That is very important, since the method a protein in the body folds identifies if a pharmaceutical will have the ability to bind to that protein and work. To put it simply, we need to know how these proteins fold if we want a drug to work. Historically, this has been an experimental procedure (biotech stock). And now, Alpha, Fold can anticipate protein folding with 92. 4% precision. That's going to make it much easier to develop drugs that do what they're developed to do. This was a breakthrough almost nobody noticed. But it's going to have extensive ramifications for treating illness. I predict that Alpha, Fold will be 98% precise by the end of 2021.
And, of course, there will be plenty of investment chances in this area, too. Moving subjects It's going to be an excellent year for bitcoin. I'm bullish on it in 2021 (biotech stocks). That stated, I still believe bitcoin will continue to be volatile. We're close to all-time highs. I would not be amazed if it pulled back maybe considerably prior to going greater - jeff brown 2020 predictions. I've been covering bitcoin for a very long time now. Among the very first research reports I ever released was on bitcoin. That remained in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $34,000 today.
However at the time of that preliminary suggestion, I titled my report "What's the Big Offer With Bitcoin?" That reveals you where the discussion was at the time. We were primarily informing readers. But that's not the big concern anymore. Now we're seeing institutional money lastly take an interest in bitcoin. Massachusetts Mutual Life Insurance coverage took a $100 million stake in bitcoin in December. This is not some little, specific niche enterprise. Mass, Mutual is a trusted 170-year-old institution. So believe about that. In five years, we went from informing readers on what bitcoin is to a company like Mass, Mutual taking a $100 million stake.
Which's a big factor I'm bullish on it this year. angel investor. Regards, Jeff Brown, Editor, The Bleeding Edge I have a perk prediction 2020 was a record year for IPOs. 552 U.S. companies went public the most in more than 20 years. These business raised an overall of $172 billion. That's an all-time high beating the previous annual record by 43%. I predict 2021 will be another record year in IPOs. There are so many excellent personal business on the edge of hitting the public markets And I have actually been working on a brand-new method for you to invest even before these companies go public.
This chance has been building over the last couple of years. I can't wait to inform you all about it. Join me tomorrow at 8 p. m. ET for my Pre-IPO Code Event to discover out all the information. Go right here to reserve your spot for free.
Emma Walsh here, managing editor of the Diary. Regular Diary readers understand that tech isn't our typical beat (jeff brown investment prediction). And when it concerns tech investing, we leave it to the professionals. Luckily, we have numerous such experts in our Rolodex. Our coworker Jeff Brown will recognize to our longtime readers. He is one of the most accomplished tech investing specialists we understand (democratic republic). In reality, he had numerous triple-digit returns in his Brownstone Research portfolios in 2015. Here's what Jeff thinks the tech sector will bring us in 2021 Each year, I like to take an appearance at the big photo and predict what's just around the corner.
That includes things like 5G networks, biotech, expert system, and much more. These patterns are experiencing exponential development and producing amazing chances for financiers. I desire to make sure all our readers are gotten ready for what's next. And with that in mind, let me draw the photo of what I see can be found in the next 12 months Our new 5G (fifth-generation) wireless networks are a topic I have actually been covering for years now. tech stocks. However in spite of what lots of readers might believe, this is a trend that's simply beginning. Despite the fact that the COVID-19 pandemic interrupted supply chains last year, an impressive 250 million 5G-enabled gadgets were still offered.
And all of this ultimately resulted in Apple postponing the release of the 5G-enabled i, Phone 12 by two months (diplomatic relations). Losing 2 months of production and sales truly impacts how many 5G devices are sold in the calendar year. When you think about all of that, selling 250 million units is exceptional. More importantly, the delays triggered by the pandemic created a lots of pent-up demand. And that demand is now going to be pressed into 2021. In fact, I anticipate that more than 500 million 5G gadgets will be shipped in 2021 - first lady. And that's not my only 5G prediction When I've discussed 5G in the past, I have actually explained its three different phases.
In Phase Two, 5G gadgets go on sale. 5G phones and other products start to reach customers. And in Stage 3, 5G services start to be provided (tech stocks). That's when we begin to see applications operating on 5G networks. Think of things like huge multiplayer games over a smart phone. That's not possible with 4G. It will be with 5G. And my 2nd 5G prediction for 2021 is that we will start Stage Three by this summer. This starts something of a virtuous cycle: Many people don't really care about the technology. However they will care if there are exciting applications that can just be accessed with a 5G phone.
That causes more 5G apps being developed. In truth, 5G is going to open up a suite of unbelievable applications: self-driving automobiles, the Internet of Things, robotic surgery, and more. All of these innovations require 5G. The financial investment opportunities moving forward will be huge. Stepping far from 5G, the next important innovation I foresee in 2021 is CRISPR hereditary modifying. CRISPR represents "clustered frequently interspaced short palindromic repeat." It's a mouthful. However it's one of the most exciting developments in biotechnology. At a high level, CRISPR is an innovation that can edit our genetic makeup as if it were software application.
The program can crash or not operate properly. CRISPR utilizes a similar idea but with our genetic code. "Typos" in our genome can result in illness. CRISPR can fix these "typos." For years, CRISPR was mostly a specific niche innovation that wasn't well comprehended. And throughout that time, there were actually only 3 business running in this space. However things are changing. CRISPR is no longer just theoretical. We're seeing actual results. We're treating illness and seeing that this innovation simply works. And as a result, a "second crop" of early-stage CRISPR business is going public and providing incredible returns. This entire industry is efficiently a greenfield chance.
There's space for numerous business to exist in this area. the legacy report predictions. And there will be more. That's my prediction for CRISPR in 2021. I forecast that two or 3 more hereditary modifying business will hold their IPOs. Sticking to biotechnology, we are seeing fantastic things occurring at the convergence of biotech and expert system (AI). Google's AI subsidiary, Deep, Mind, simply announced at the end of 2020 that its most current Alpha, Fold software application can properly forecast the folding of a protein based entirely on its amino acid sequence with 92. 4% precision. That is essential because the method a protein in the human body folds determines if a pharmaceutical will be able to bind to that protein and work.
Historically, this has been a trial-and-error process. And now, Alpha, Fold can predict protein folding with 92. 4% accuracy. That's going to make it a lot easier to create drugs that do what they're developed to do. And here's my next forecast. I forecast that Alpha, Fold will be 98% precise by the end of 2021. And we will see not just one however several drug therapies produced utilizing this technology. This was one of those developments that practically nobody noticed. But it's going to have profound ramifications for treating disease. And, of course, there will be lots of investment chances in this area, too.
It's going to be an excellent year for bitcoin. I'm bullish on it in 2021. That said, I still think bitcoin will continue to be volatile. We're close to all-time highs. I wouldn't be shocked if it pulled back possibly substantially before going higher. I've been covering bitcoin for a very long time now. One of the very first research reports I ever published was on bitcoin - biotech stocks. That remained in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $40,000 today. So that's a 16,500%+ return on investment for anybody who followed my suggestion. But at the time of that preliminary recommendation, I entitled my report, "What's the Big Deal With Bitcoin?" That reveals you where the discussion was at the time.
However no one is asking that question any longer. Now, we're seeing institutional cash finally taking an interest in bitcoin. The huge news was that Massachusetts Mutual Life Insurance took a $100 million stake in bitcoin in December. This is not some small, specific niche enterprise. biotech stock. Mass, Mutual is a 150-year-old organization. So consider that. In 5 years, we went from informing readers on what bitcoin is to a business like Mass, Mutual taking a $100 million stake. The institutional adoption of bitcoin will continue. Which's a big reason why I'm bullish on it this year. Regards, Jeff Brown, Editor, The Bleeding Edge I have another reward forecast In 2021, we're going to have another record year in IPOs. One site reports that Jeff Brown is worth about $27. 5 million and declares the information depends on date since February 2021, but we might not separately verify this claim. Provided Jeff Brown's past, he likely has a substantial net worth, however we can't hammer down a precise figure at this minute. Brown is best understood for his sage-like ability to pick winning technology stocks. He spent more than 25 years looking into innovation business like Qualcomm, NXP semiconductors, and Juniper Networks. Brown's extensive experience gives him an outstanding point of view on the marketplace. He's constantly on the hunt for new chances, and he shares a lot of his finest picks in the Future Report.
That's high praise, but it's not absurdly reasoned. Brown has an excellent reputation as a stock-picker, and he successfully predicted a few of the most significant financial events of the past 20 years. Although he does not appear to launch his choices to the general public, the service's success is a direct indication of Brown's stock-picking prowess. No one on Wall Street gets it best each time, however Jeff Brown's precise forecasts have made him legions of dedicated followers. That states a lot about his capability. The Near Future Report is published by Brownstone Research study, a popular monetary research study publisher. Brownstone Research study uses numerous research study services with a wide array of expertises - jeff brown prediction for 2021.
The company is likewise associated with Bonner & Partners, another well-respected research publisher - jeff brown top biotech stock 2021. On its website, Brownstone says its mission is to provide retail financiers with professional-grade research study: "For too long, the very best investment research study has actually not been readily available to specific investors. It has actually been usually booked for financial investment banks, hedge funds, personal equity, and high-net-worth customers. jeff brown predictions 2021. The mission of Brownstone Research is to make that kind of proprietary research study available to any investors aiming to acquire an edge in the markets. The objective is basic to provide unique and successful financial investment research found no place else." -Brownstone Research study website excerpt from the Jeff Brown is the creator of Brownstone Research, and he also serves as the company's Chief Investment Analyst.
With Brown guiding the ship, Brownstone Research study is a powerhouse publisher with lots to offer its clients. After years of stable success at the helm of top-tier companies like Tesla and Space, X, Elon Musk is a household name throughout most of America. If you know even a bit about the marketplace, you understand that he has a reputation as a King Midas of sorts. exponential growth. Whatever he touches turns to gold! Jeff is aware of Elon Musk's executive prowess, so he always has an eye out for the Silicon Valley rock star's next relocation. This time, Jeff has an early lead on Elon's next huge job.
In truth, Brown thinks S.A.V. biotech stock. might be "the greatest trend of the 2020s, and he's not alone. Have a look at these quotes from other well-known S.A.V. bulls: Elon's next huge act will be weding 2 cutting-edge technologies: expert system and electric cars and trucks. Musk hopes the mix will help him develop the first fully-autonomous, self-driving automobiles ever. It's nothing except the automotive market's Holy Grail. As you know, electrical vehicles and self-driving vehicle stocks have actually been substantial this year, however the Wall Street machine has actually approved hype without much concrete outcome. Despite a drastic increase in competition over the previous couple of years, Brown still thinks Musk has the very best possibility of putting all of it together.
tech might be the magic string that ties it all together. S.A.V. means Shared Autonomous Vehicle, and it could be the future of transportation. Generally, this technology would allow you to rent your automobile as a self-governing, self-driving taxi when you're not using it. You merely leave the automobile and press a button on an app that tells the car to "join the fleet." Next thing you know, you're unwinding on your couch while your vehicle shuttles ride-sharers around town. Most importantly, you get to keep a large piece of the revenues. It sounds ridiculous, but it might be closed than you think.